Synedgen — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $6.8M

Overview

Synedgen is a private, clinical-stage biotech founded in 2008, headquartered in Claremont, California. The company's core technology is the Multivalent Innate Immune Signaling Target (MIIST) platform, which generates glycopolymers designed to repair mucosal and dermal barriers. Its lead program, MIIST305, is a clinic-ready oral therapeutic for GI injury, with demonstrated preclinical efficacy in models like Acute Radiation Syndrome. The company is pre-revenue and is advancing its pipeline through internal development.

Infectious DiseaseWound HealingGastrointestinal

Technology Platform

Multivalent Innate Immune Signaling Target (MIIST) platform: a regenerative modality using engineered glycopolymers to repair mucosal and dermal barriers by modulating innate immune signaling.

Funding History

3

Total raised:$6.8M

Series A$5MUndisclosedMar 15, 2015

Grant$1.5MNational Institutes of HealthSep 15, 2014

Grant$300KNational Institutes of HealthJun 15, 2012

Opportunities

Large unmet need in GI barrier repair for conditions like Acute Radiation Syndrome, chemotherapy-induced mucositis, and inflammatory bowel disease (IBD).

The platform's regenerative mechanism could offer a first-in-class treatment paradigm, supported by potential government contracts for medical countermeasures.

Risk Factors

High translational risk moving from preclinical to human trials for a first-in-class mechanism.

Financial dependency on raising capital for clinical development.

Potential regulatory challenges in defining and measuring endpoints for mucosal repair.

Competitive Landscape

The field of mucosal healing is emerging but competitive, with other biotechs and large pharma exploring anti-integrins, cytokines, and growth factors. Synedgen's glycopolymer approach is distinct, but it may face competition from more advanced clinical programs in IBD and mucositis.

More companies in Small Molecule Drugs →More companies in United States →